Nuvation Bio — Third Quarter 2026 Earnings Summary

Nuvation Bio reported third-quarter 2026 total revenue of $45.0 million, comprising $27.5 million in net product revenue from its ROS1 inhibitor IBTROZI and $17.5 million in collaboration and license agreement revenue. The company's cash, cash equivalents, and marketable securities totaled $663.4 million as of September 30, 2026, following the exercise of a greenshoe option on convertible senior notes in July. IBTROZI maintained its position as the market leader in new patient starts for ROS1+ non-small cell lung cancer, while the FDA granted Fast Track Designation to the investigational drug safusidenib for IDH1-mutant glioma. The company recorded a net loss of $41.9 million for the quarter, driven by increased research and development and selling, general, and administrative expenses.